| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 5. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | saxagliptin/metformin (Komboglyze®) |
| Formulation | 2.5 mg/850 mg film-coated tablet; 2.5 mg/1,000 mg film-coated tablet |
| Reference number | 1976 |
| Indication | In combination with a sulphonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in adult patients aged 18 years and older with type 2 diabetes mellitus when the maximally tolerated dose of both metformin and the sulphonylurea does not provide adequate glycaemic control |
| Company | Bristol-Myers Squibb Pharmaceuticals Ltd/AstraZeneca UK Ltd |
| BNF chapter | Endocrine system |
| Assessment type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 07/01/2014 |